

Short Name	Full Title + Study Description	Type	Investigator	Contact
GIBBY VS. PARKY 2018-062	<b>Brain-Derived Neurotrophic Factor (BDNF) Precision Medicine for Parkinson's Disease- Levodopa Study</b>	Observational	Sriram, Ashok	Julia Reddy <a href="mailto:Julia.Reddy@spectrumhealth.org">Julia.Reddy@spectrumhealth.org</a> 616.486.2022
<p><i>The purpose of this trial is to look at genes (DNA) and how they respond to the antiparkinsonian medication that you are presently taking (Sinemet, also known as carbidopa-levodopa). Participants with Parkinson's disease will have a single office visit with ON/OFF testing and will give a saliva sample.</i></p>				
PASADENA 2017-194	<b>Phase 2 study of Anti <math>\alpha</math>-Synuclein Antibody in Early Parkinson's disease</b>	Treatment	Coleman, Robert	Jessica Gallavin <a href="mailto:Jessica.Gallavin@spectrumhealth.org">Jessica.Gallavin@spectrumhealth.org</a> 616.486.7492
<p><i>The purpose of this multicenter, randomized, double-blind, placebo-controlled, Phase 2 trial is to evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 (all-participants-on-RO7046015-treatment) for an additional 260 weeks.</i></p> <p><a href="#">For More Information Click Here</a></p>				